Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | Chief Financial Officer | March 04, 2024 | March 05, 2024 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | EVP, Chief Financial Officer | July 22, 2026 | July 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date March 04, 2024 · Filed March 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 101,479 |
Reported balance
After 2024-03-04 transaction · row 1
1 source rowRow 1 · 2024-03-04 · Sale · Disposed 2,447 · Balance 101,479 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023.
Intellia Therapeutics, Inc.
Report date July 22, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 148,175 |
Reported balance
After 2026-07-22 transaction · row 1
1 source rowRow 1 · 2026-07-22 · Sale · Disposed 8,111 · Balance 148,175 F1: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2026 Filed Jul 24, 2026 21:26 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 8,111 | $11.25 | $91,248.75 |
DisclosureSEC source: 0001193125-26-316279 · ownership.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,175 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 21:01 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 4,677 | $18.00 | $84,186.00 |
DisclosureSEC source: 0001821530-26-000002 · ownership.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,286 F1 · kind: The reported sale of 4,677 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 8, 2025. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:17 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 87,543 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0001193125-26-088254 · ownership.xml · derivative · entry 2 Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,543 Underlying: Common Stock · 87,543 shares Expires 2036-02-29 F2 · derivative.exercise_date: This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:17 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 61,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088254 · ownership.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,963 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:02 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 6,379 | $9.21 | $58,750.59 |
DisclosureSEC source: 0001193125-26-006275 · ownership.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,683 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| July 23, 2025 Filed Jul 25, 2025 20:05 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 7,462 | $14.02 | $104,617.24 |
DisclosureSEC source: 0000950170-25-098774 · ownership.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,062 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2025, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 67,429 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0000950170-25-032192 · ownership.xml · derivative · entry 2 Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,429 Underlying: Common Stock · 67,429 shares Expires 2035-02-28 F2 · derivative.exercise_date: This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 47,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032192 · ownership.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,524 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 20:17 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 96,219 | $0.00 Strike: $25.33 | $0.00 |
DisclosureSEC source: 0000950170-24-086061 · ownership.xml · derivative · entry 2 Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,219 Underlying: Common Stock · 96,219 shares Expires 2034-07-21 F2 · derivative.exercise_date: This option was granted on July 22, 2024 with respect to shares of Common Stock, with 33% vesting on July 22, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 20:17 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 66,324 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-086061 · ownership.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,324 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:24 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 2,447 | $7.77 | $19,013.19 |
DisclosureSEC source: 0000950170-24-025992 · ownership.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,479 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:09 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 425,000 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0000950170-24-010485 · ownership.xml · derivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| January 29, 2024 Filed Jan 30, 2024 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,849 | $5.00 | $9,245.00 |
DisclosureSEC source: 0000950170-24-008803 · ownership.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,926 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 21:29 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 7,028 | $4.37 | $30,712.36 |
DisclosureSEC source: 0000950170-24-003647 · ownership.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,775 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021 and 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $4.02 to $4.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 5,182 | $3.66 | $18,966.12 |
DisclosureSEC source: 0000950170-24-000874 · ownership.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,803 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,585 | $3.50 | $5,547.50 |
DisclosureSEC source: 0001209191-23-059103 · doc4.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,985 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 4,718 | $2.80 | $13,210.40 |
DisclosureSEC source: 0001209191-23-046691 · doc4.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,570 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the Reporting Person on August 17, 2020. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold from $2.76 to $2.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 21:18 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 5,182 | $4.83 | $25,029.06 |
DisclosureSEC source: 0001209191-23-041607 · doc4.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,288 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:15 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 425,000 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0001209191-23-007503 · doc4.xml · derivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2033-02-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2023, such that all of the shares shall be fully vested and exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 21:06 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 7,331 | $5.24 | $38,414.44 |
DisclosureSEC source: 0001209191-23-002975 · doc4.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,470 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021 and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $5.12 to $5.36 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 22:58 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 432 | $30.41 | $13,137.12 |
DisclosureSEC source: 0001209191-22-046929 · doc4.xml · nonDerivative · entry 2 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,801 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the Reporting Person on August 17, 2020. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 22:58 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 4,703 | $29.75 | $139,914.25 |
DisclosureSEC source: 0001209191-22-046929 · doc4.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,233 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the Reporting Person on August 17, 2020. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold from $29.29 to $30.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:35 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 53,058 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000899243-22-003443 · doc4.xml · derivative · entry 2 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,058 Underlying: Common Stock · 53,058 shares Expires 2032-01-24 F2 · derivative.exercise_date: The shares subject to this option vest in 48 equal month installments beginning on February 1, 2022 such that this option will be fully exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:35 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 33,302 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-003443 · doc4.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,936 F1 · security: Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2023, January 8, 2024, January 8, 2025 and January 8, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:06 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 390 | $49.16 | $19,172.40 |
DisclosureSEC source: 0001209191-22-003168 · doc4.xml · nonDerivative · entry 2 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,634 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $48.83 to $49.31 per share. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:06 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,380 | $48.25 | $66,585.00 |
DisclosureSEC source: 0001209191-22-003168 · doc4.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,024 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $47.71 to $48.59 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 21:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,437 | $0.00 Strike: $35.52 | $0.00 |
DisclosureSEC source: 0001209191-21-070768 · doc4.xml · derivative · entry 3 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,238 Underlying: Common Stock · 14,437 shares Expires 2030-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021. F2 · derivative.exercise_date: The option shall vest as to 25% of the underlying shares on August 17, 2021 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 21:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 15,977 | $60.00 | $958,620.00 |
DisclosureSEC source: 0001209191-21-070768 · doc4.xml · nonDerivative · entry 2 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,404 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 21:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 14,437 | $35.52 | $512,802.24 |
DisclosureSEC source: 0001209191-21-070768 · doc4.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 22:41 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 59,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066159 · doc4.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,944 F1 · kind: These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement. Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 20:14 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,325 | $0.00 Strike: $35.52 | $0.00 |
DisclosureSEC source: 0001209191-21-058176 · doc4.xml · derivative · entry 3 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,675 Underlying: Common Stock · 17,325 shares Expires 2030-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021. F2 · derivative.exercise_date: The option shall vest as to 25% of the underlying shares on August 17, 2021 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date. Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 20:14 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 19,460 | $62.53 | $1,216,833.80 |
DisclosureSEC source: 0001209191-21-058176 · doc4.xml · nonDerivative · entry 2 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,404 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021. Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 20:14 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 17,325 | $35.52 | $615,384.00 |
DisclosureSEC source: 0001209191-21-058176 · doc4.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 63 | $90.00 | $5,670.00 |
DisclosureSEC source: 0001209191-21-052742 · doc4.xml · nonDerivative · entry 3 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,539 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the reporting person on August 17, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,474 | $88.65 | $130,670.10 |
DisclosureSEC source: 0001209191-21-052742 · doc4.xml · nonDerivative · entry 2 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,602 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the reporting person on August 17, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.47 to $89.26 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,937 | $87.90 | $170,262.30 |
DisclosureSEC source: 0001209191-21-052742 · doc4.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,076 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the reporting person on August 17, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.42 to $88.33 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 23:18 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 6,851 | Not disclosed Strike: $109.01 | Not disclosed |
DisclosureSEC source: 0001209191-21-004953 · doc4.xml · derivative · entry 2 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,851 Underlying: Common Stock · 6,851 shares Expires 2031-01-20 F3 · price: Not applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments beginning on February 1, 2021 such that this option is fully exercisable on January 1, 2025. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 23:18 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon stock | 18,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004953 · doc4.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,013 F1 · security: Award of restricted stock units ("RSUs") that vests with respect to the 1/4th of the underlying shares on each of January 8, 2022, January 8, 2023, January 8, 2024, and January 8, 2025. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:12 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $35.52 | $0.00 |
DisclosureSEC source: 0001209191-20-047483 · doc4.xml · derivative · entry 2 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2030-08-17 F2 · derivative.exercise_date: The option shall vest as to 25% of the underlying shares on the first anniversary of the grant date and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:12 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047483 · doc4.xml · nonDerivative · entry 1 Dulac Edward J III · CIK 0001821530 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · kind: Exempt grant of restricted stock units pursuant to the Issuer's Inducement Equity Plan. The units will vest in four annual installments after the grant date, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.